Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$4.99 - $8.96 $13,637 - $24,487
2,733 Added 5.47%
52,733 $332,000
Q1 2022

May 13, 2022

BUY
$3.84 - $9.74 $192,000 - $487,000
50,000 New
50,000 $415,000

Others Institutions Holding EIGR

About Eiger BioPharmaceuticals, Inc.


  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $418M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Parkman Healthcare Partners LLC Portfolio

Follow Parkman Healthcare Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.